ArticleBiomarker research2026
Pannexin 1 expression in circulating progenitor marker-positive cells is associated with senescence and cardiovascular risk.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUpregulation of Pannexin 1 (Panx1) has been reported in senescent human endothelial colony-forming cells. We examined whether Panx1 served as a potential biomarker of senescence in peripheral blood mononuclear cells (PBMCs) expressing progenitor markers and its association with inflammation, nitric oxide (NO), and cardiovascular risk.
methodsPanx1 transcripts were assessed in PBMCs from 60 non-diabetic donors (20 aged 20-30 years and 40 aged ≥ 65 years). ECFCs were examined for Panx1-NO interaction. A separate flow-cytometry cohort comprised 50 donors (25 young and 25 elderly) targeting CD34
resultsHigher Panx1 transcript levels existed in PBMCs of the elderly versus young donors. Among the elderly, higher Panx1 transcript levels existed in those respectively with increased fasting glucose (> 100 versus 100 mg/dL) and moderate-to-high FRS (versus low FRS). Panx1 interacted with NO in ECFCs. The proportion of CD34
conclusionsPanx1 in selected circulating progenitor-cell populations is associated with cellular senescence and cardiovascular risk in non-diabetic elderly individuals. Panx1 as a candidate cellular senescence-associated biomarker requires prospective validation.
Indexed as
Identifiers
42855730What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.